Home › Funds › Propel Bio Management, LLC › CRVS
Propel Bio Management, LLC position in CRVS
CORVUS PHARMACEUTICALS INC · Health Care
Propel Bio Management, LLC reported holding 264,310 shares of CRVS (CORVUS PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$3.0M, representing 1.61% of its reported portfolio and ranking #19 among its reported holdings. Propel Bio Management, LLC has disclosed CRVS holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Propel Bio Management, LLC's CRVS position evolved
Propel Bio Management, LLC first disclosed a stake in CRVS in Q1 2026 at 85,791 shares (US$1.3M). The position peaked in Q3 2026 at 264,310 shares, worth US$3.0M. Across 3 filings, Propel Bio Management, LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 264,310 shares valued at US$3.0M — an increase of 193,930 shares quarter over quarter.. Notable position changes include a 276% increase in Q3 2026 (shares fell 8% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 85.79K | $1.25M | New |
| Q2 2026 | 70.38K | $1.05M | Reduce |
| Q3 2026 | 264.31K | $3.04M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CRVS and 13F data
CRVS (CORVUS PHARMACEUTICALS INC) is a Health Care company. 66 other funds we track also report a position in CRVS — the largest reported positions include ORBIMED ADVISORS LLC (US$107.0M), ADAMS STREET PARTNERS LLC (US$48.9M), PERCEPTIVE ADVISORS LLC (US$39.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CRVS
- ORBIMED ADVISORS LLC 7.17M sh · $107.05M · Q2 2026
- ADAMS STREET PARTNERS LLC 3.28M sh · $48.94M · Q2 2026
- PERCEPTIVE ADVISORS LLC 2.67M sh · $39.85M · Q2 2026
- Deep Track Capital, LP 2.49M sh · $37.23M · Q2 2026
- Vivo Capital, LLC 2.81M sh · $32.32M · Q3 2026
- BRAIDWELL LP 2.13M sh · $31.77M · Q2 2026
- Foresite Capital Management VI LLC 1.83M sh · $27.36M · Q2 2026
- Boxer Capital Management, LLC 1.10M sh · $16.43M · Q2 2026
- Catalio Capital Management, LP 1.08M sh · $16.15M · Q2 2026
- Eversept Partners, LP 747.99K sh · $11.18M · Q2 2026
- DCF Advisers, LLC 641.50K sh · $7.39M · Q3 2026
- Nextech Invest Ltd. 450.00K sh · $6.72M · Q2 2026
More on Propel Bio Management, LLC
FAQ
How long has Propel Bio Management, LLC held CRVS?
Propel Bio Management, LLC has disclosed CRVS holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Propel Bio Management, LLC's current position in CRVS?
As of Q3 2026, Propel Bio Management, LLC holds 264.31K shares of CRVS (CORVUS PHARMACEUTICALS INC), valued at $3.04M, representing 1.61% of its reported portfolio and ranking #19.
Has Propel Bio Management, LLC been buying or selling CRVS?
In the latest 13F filing (Q3 2026), Propel Bio Management, LLC increased its position in CRVS. The position peaked in Q3 2026 at 264.31K shares.
Which other funds hold CRVS?
Other major institutional holders of CRVS include ORBIMED ADVISORS LLC, ADAMS STREET PARTNERS LLC, PERCEPTIVE ADVISORS LLC, among 66 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.